Phospholipase A2 receptor 1 promotes lung cell senescence and emphysema in obstructive lung disease

BACKGROUND: Cell senescence is a key process in age-associated dysfunction and diseases, notably chronic obstructive pulmonary disease (COPD). We previously identified phospholipase A2 receptor 1 (PLA2R1) as a positive regulator of cell senescence acting via Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling. Its role in pathology, however, remains unknown. Here, we assessed PLA2R1-induced senescence in COPD and lung emphysema pathogenesis. METHODS: We assessed cell senescence in lungs and cultured lung cells from patients with COPD and controls subjected to PLA2R1 knockdown, PLA2R1 gene transduction and treatment with the JAK1/2 inhibitor ruxolitinib. To assess whether PLA2R1 upregulation caused lung lesions, we developed transgenic mice overexpressing PLA2R1 (PLA2R1-TG) and intratracheally injected wild-type mice with a lentiviral vector carrying the Pla2r1 gene (LV-PLA2R1 mice). RESULTS: We found that PLA2R1 was overexpressed in various cell types exhibiting senescence characteristics in COPD lungs. PLA2R1 knockdown extended the population doubling capacity of these cells and inhibited their pro-inflammatory senescence-associated secretory phenotype (SASP). PLA2R1-mediated cell senescence in COPD was largely reversed by treatment with the potent JAK1/2 inhibitor ruxolitinib. Five-month-old PLA2R1-TG mice exhibited lung cell senescence, and developed lung emphysema and lung fibrosis together with pulmonary hypertension. Treatment with ruxolitinib induced reversal of lung emphysema and fibrosis. LV-PLA2R1-treated mice developed lung emphysema within 4 weeks and this was markedly attenuated by concomitant ruxolitinib treatment. CONCLUSIONS: Our data support a major role for PLA2R1 activation in driving lung cell senescence and lung alterations in COPD. Targeting JAK1/2 may represent a promising therapeutic approach for COPD.

  • Beaulieu, D.
  • Attwe, A.
  • Breau, M.
  • Lipskaia, L.
  • Marcos, E.
  • Born, E.
  • Huang, J.
  • Abid, S.
  • Derumeaux, G.
  • Houssaini, A.
  • Maitre, B.
  • Lefevre, M.
  • Vienney, N.
  • Bertolino, P.
  • Jaber, S.
  • Noureddine, H.
  • Goehrig, D.
  • Vindrieux, D.
  • Bernard, D.
  • Adnot, S.

Keywords

  • Animals
  • Cellular Senescence
  • *Emphysema
  • Humans
  • Lung
  • Mice
  • *Pulmonary Disease, Chronic Obstructive/drug therapy
  • *Pulmonary Emphysema
  • Receptors, Phospholipase A2
  • A. Attwe has nothing to disclose. Conflict of interest: M. Breau has nothing to
  • disclose. Conflict of interest: L. Lipskaia has nothing to disclose. Conflict of
  • interest: E. Marcos has nothing to disclose. Conflict of interest: E. Born has
  • nothing to disclose. Conflict of interest: J. Huang has nothing to disclose.
  • Conflict of interest: S. Abid has nothing to disclose. Conflict of interest: G.
  • Derumeaux has nothing to disclose. Conflict of interest: A. Houssaini has nothing
  • to disclose. Conflict of interest: B. Maitre has nothing to disclose. Conflict of
  • interest: M. Lefevre has nothing to disclose. Conflict of interest: N. Vienney
  • has nothing to disclose. Conflict of interest: P. Bertolino has nothing to
  • disclose. Conflict of interest: S. Jaber has nothing to disclose. Conflict of
  • interest: H. Noureddine has nothing to disclose. Conflict of interest: D. Goehrig
  • has nothing to disclose. Conflict of interest: D. Vindrieux has nothing to
  • disclose. Conflict of interest: D. Bernard has nothing to disclose. Conflict of
  • interest: S. Adnot has nothing to disclose.
Publication details
DOI: 10.1183/13993003.00752-2020
Journal: Eur Respir J
Number: 2
Work Type: Original
Access number: 33509955
See publication on PubMed
chevron-down